President Donald Trump launched a barrage of steep tariffs, dubbing it “Liberation Day” and igniting a full-scale trade war ...

If you know someone battling depression or Alzheimer’s, Dr. Herriot Tabuteau might just become your new hero. For years, ...

At the recent American Academy of Neurology (AAN) 2025 annual meeting, Axsome Therapeutics (Nasdaq: AXSM) presented promising data for AXS-05 (bupropion + dextromethorphan) in treating agitation ...

President Trump’s newly announced tariff policy has done more than just push the stock markets deeper into correction territory — the sudden ...

Agitated patients are often prescribed antipsychotic medications and sedatives off-label, but this can pose a risk to the ...

Axsome Therapeutics, Inc.’s AXSM share price has dipped by 8.23%, which has investors questioning if this is right time to ...

Jefferies initiated coverage of Axsome Therapeutics (AXSM) with a Buy rating and $200 price target The company currently markets three central ...

Axsome Therapeutics posted mixed results for its experimental depression treatment on Tuesday, leading Axsome stock to dive.

In light of these findings, Axsome has announced plans to initiate a Phase 3 trial focusing exclusively on MDD patients with EDS in 2025. This decision comes after observing clinically meaningful and ...

Meanwhile, BofA Securities kept a Buy rating with a $174 target, focusing on the strong performance of Axsome’s Auvelity in the major depressive disorder market and its potential expansion into ...

Axsome's Phase 3 trial for solriamfetol in MDD did not meet its primary endpoint, but positive data in severe EDS patients supports plans for a new study in 2025.